Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Background:</b> Phosphatidylinositol 3-kinase (PI3K) pathway activation plays a key role in tumorigenesis and has been associated with poor prognosis and resistance to multiple therapies in various cancers.
|
31741715 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<i>N</i>-Glycan deletion on β4-integrin impaired β4-dependent cancer cell migration, invasion, and growth <i>in vitro</i> and diminished tumorigenesis and proliferation <i>in vivo</i> The reduced abilities of β4-integrin were accompanied with decreased phosphoinositol-3 kinase (PI3K)/Akt signals and were restored by the overexpression of the constitutively active p110 PI3K subunit.
|
29549127 |
2018 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
(2007) use mouse models of Ras-mediated tumorigenesis to show that the interaction of Ras with a single isoform of phosphatidylinositol 3-kinase (PI3K), called p110alpha (PIK3CA), is critical for tumor formation.
|
17540164 |
2007 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
(2008) identify specific functions of the p110beta isoform of PI3K in glucose metabolism, cellular proliferation, and tumorigenesis.
|
18762017 |
2008 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
14-3-3ζ is involved in the regulation of PI3K/Akt pathway which is closely associated with carcinogenesis.
|
29439255 |
2018 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K plays an important role in tumorigenesis.
|
16839745 |
2006 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K/PTEN signaling in tumorigenesis and angiogenesis.
|
17964232 |
2008 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K pathway activation may drive tumorigenesis in a subset of MCC and screening these tumors for PIK3CA mutations could help identify patients who may respond to treatment with PI3K pathway inhibitors.
|
22261808 |
2012 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K/AKT/mTOR pathway plays a key role in the tumorigenesis of many human cancers including prostate cancer.
|
22491797 |
2012 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K pathway activation may occur as part of primary tumorigenesis, or as an adaptive response (via molecular alterations or increased phosphorylation of pathway components) that may lead to resistance to anticancer therapies.
|
23551097 |
2013 |
Carcinogenesis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
PI3K pathway mutation is prominent in proximal colon cancers, with PIK3CA exon 20 and PTEN mutations associated with features of the sessile-serrated pathway (MSI-H/CIMP-H/BRAF(mut)), and PIK3CA exon 9 (and to a lesser extent exon 20) mutation associated with features of the traditional serrated pathway (CIMP-L/KRAS(mut)) of tumorigenesis.
|
23633456 |
2013 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis.
|
24449057 |
2014 |
Carcinogenesis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
PI3K pathway mutation is important to cervical carcinogenesis in Latin America.
|
26080840 |
2015 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K/AKT signaling pathway plays an important role in tumorigenesis and regulates critical cellular functions including survival, proliferation and metabolism.
|
26995633 |
2016 |
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
PI3K is activated in cancer and affects several aspects of oncogenesis.
|
28176240 |
2017 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K/AKT/mTOR signaling pathway plays a crucial role in tumorigenesis and development.
|
29424922 |
2018 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K/Akt/mTOR pathway is crucial for carcinogenesis and its inhibitors have made a great progress in cancer treatment.
|
29625382 |
2018 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K/Akt/mTOR Signaling Pathway and the Biphasic Effect of Arsenic in Carcinogenesis.
|
29769245 |
2018 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K-directed therapeutic interference showed that MLS cell proliferation and viability significantly depended on PI3K-mediated signals <i>in vitro</i> and <i>in vivo</i> Our preclinical study underlines the elementary role of PI3K/Akt signals in MLS tumorigenesis and provides a molecularly based rationale for a PI3K-targeted therapeutic approach which may be particularly effective in the subgroup of tumors carrying activating genetic alterations in PI3K/Akt signaling components.
|
30787173 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K/Akt/mTOR signalling is an important event in colorectal carcinogenesis.
|
31215384 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K/AKT is an imperative pathway involved in theproliferation and tumorigenesis of cancer cells and herein it was found that Scopoletin could inhibit this pathway.
|
31424653 |
2020 |
Carcinogenesis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
A model linking the main tumorigenesis (Wnt/TGF-beta-BMP/LKB-1/PI3K-AKT) pathways and a strategy for gene testing are proposed.
|
18774731 |
2009 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias.
|
24244612 |
2013 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Aberrant activation and mutation status of proteins in the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and the mitogen activated protein kinase (MAPK) signaling pathways have been linked to tumorigenesis in various tumors including urothelial carcinoma (UC).
|
22110663 |
2011 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Aberrant elevated PI3K activation has been reported to promote the tumorigenesis of breast cancer, but the mechanisms underlying are still needed to be elucidated.
|
30671946 |
2019 |